Dr Peter McCullough: Prescription and Over-the-Counter Treatments for Long COVID Syndrome (2023)
Get link
Facebook
X
Pinterest
Email
Other Apps
By
Editorial Team
-
Over three years into the pandemic with nearly the entire country having become
sick with SARS-CoV-2, a virus engineered to invade the body, there are millions
suffering with long-hauler syndrome. Approximately half of patients admitted to
the ICU with COVID-19 will have post-COVID syndrome which is now understood to
be due to persistence of the SARS-CoV-2 Spike protein within cells, tissues, and
organs. Those vaccinated have been additionally loaded with Spike, so may have
even a worse course with prolonged symptoms including fatigue, lethargy, brain
fog, muscle loss, skin and hair changes, sleeplessness, and effort intolerance.
The magnitude of the problem has driven an all-encompassing search for
management strategies to resolve the syndrome(s).
Hope is on the
horizon with a preprint paper published by Halma et al summarizing the
prescription drug and over-the-counter candidates for therapy. In my practice, I
stylize the approach based on the patient and how recent the COVID-19 infection
was in their history. If there are lingering signs of infection, then a course
of full dose ivermectin can be considered. Aspirin is reasonable given increased
rates of heart attack and stroke after the illness. I have found the colchicine
appears to have an important role in pleurodynia or chest wall discomfort.
Additionally it is used with corticosteroids in vaccine-induced myopericarditis.
Low-dose naltrexone has been reported to ameliorate fatigue and inanition.
Metformin has supportive data and would be appropriate in pre-diabetes and those
with diabetes mellitus.
Halma, M.T.; Plothe, C.; Lawrie, T. Strategies for the
Management of Spike Protein-Related Pathology. Preprints 2023,
2023030344. https://doi.org/10.20944/preprints202303.0344.v1.
From the OTC list, I have found nattokinase, the Japanese product derived
from natto (a traditionalJapanese food made from whole soybeans that have been fermented with Bacillus subtilis var. natto.) to be the most compelling and scientifically supported approach to
clear Spike protein out of the body via proteolytic degradation. A host of
cellular protective, anti-oxidant approaches are listed with vitamin C and
NAC being readily available and widely used.
Nattokinase and Spike Protein
Tanikawa et al. examined the effect of nattokinase on the spike protein of SARS-CoV-2. In
the first experiment, they demonstrated that spike was degraded in a time
and dose-dependent manner in a cell lysate preparation that could be
analogous to a vaccine recipient. The second experiment demonstrated that
nattokinase degraded the spike protein in SARS-CoV-2 infected cells. This
was reproduced in a similar study done by Oba and colleagues in 2021.
Tanikawa T, Kiba Y, Yu J, Hsu K, Chen S, Ishii A, Yokogawa T, Suzuki R,
Inoue Y, Kitamura M. Degradative Effect of Nattokinase on Spike Protein of
SARS-CoV-2. Molecules. 2022 Aug 24;27(17):5405. doi:
10.3390/molecules27175405. PMID: 36080170; PMCID: PMC9458005.
Nattokinase is dosed in fibrinolytic units (FU) per gram and can vary
according to purity. Kurosawa and colleagues have shown in humans that after
a single oral dose of 2000 FU D-dimer concentrations at six, and
eight hours, and blood fibrin/fibrinogen degradation products at four hours
after administration elevated significantly (p < 0.05, respectively).
Thus
an empiric starting dose could be 2000 FU twice a day. Full pharmacokinetic
and pharmacodynamic studies have not been completed, but several years of
market use as an over-the-counter supplement suggests nattokinase is safe
with the main caveat being excessive bleeding and cautions with concurrent
antiplatelet and anticoagulant drugs.
Ivermectin and Spike Protein
Former NIH researcher David Scheim, PhD, early in the pandemic proposed that
SARS-CoV-2 Spike protein was acting like a grappling hook pulling together
circulating red blood cells (RBSc) into long chains and clumps in a process
called hemagglutination (HA). This explained why the red blood cells could
not carry oxygen normally and was congruent with the finding of micro blood
clots in the lungs. Recently, Boschi et al have provided additional support
for this mechanism (source).
According to the authors: “Ivermectin blocked HA when
added to RBCs prior to spike protein and reversed HA when added
afterwards.”
In another spectacular publication, Stone et al,
describes the prompt improvement of oxygenation in patients with ivermectin
(source).
The published oxygenation curves from multiple studies clearly
show this physiological effect of ivermectin occurs so rapidly, it must be
explained by a direct anti-Spike protein effect of ivermectin. An
anonymous video of a critically ill man
demonstrates the very effect that Scheim, Stone, Hazan, and Babalola have
described in the Figure above. So for the next critically ill patient with
COVID-19, if the opportunity presents itself, push for the administration of
ivermectin. This is the only published therapy for COVID-19 that improves
oxygen saturation while the patient mounts a recovery. As in this man, it
may be the critical factor for a turnaround and a chance to walk out of the
hospital.
Key Takeaway
Patients should push their doctors to refer them to clinical trials, and
when that is not feasible, then empiric therapy can be pursued. It is
important to realize that in the absence of completed large randomized
placebo controlled randomized trials, which are easily 5 or more years away
in the future, no therapeutic claims can be made. In the meantime we must be
perceptive as patients and open-minded as clinicians to come up with
reasonable approaches that can be used to help those sick now with
post-COVID syndromes.
Though there are many long haulers treatment protocols out there, we
consider and recommend the I-Recover protocol as one of the best.
Given the lack of clinical trials of long-haul COVID-19 syndrome,
these recommendations are based on the abnormal changes within the
body associated with the COVID-19 disease and post viral illnesses
along with the collective experience of FLCCC members.
This protocol has also been used to treat post-vaccine inflammatory
syndromes with similar success. As with all FLCCC Alliance protocols,
the components, doses, and durations will evolve as more clinical data
accumulates.
Due to the marked overlap between long COVID and post-vaccine syndrome,
please refer to the I-RECOVER Post-Vaccine Treatment protocol for detailed treatment strategies.
The Wellness Company's acclaimed Spike Support Formula contains scientifically-researched
ingredients, including nattokinase, black seed oil, green tea extract
and selenium.
These ingredients are known for their ability
to dissolve spike protein, prevent it from binding to cells, and
repair tissue.
Recommended to maintain daily health for
anyone exposed to COVID, vaccines, or shedding – and may help your
body repair itself and remain at optimal health.
Where to buy Spike Support Formula: Spike Support Formula is available on The Wellness
Company's website. Here is the link: Spike Support Formula (Long Haul Formula)
Note: To get 10% OFF, please use this coupon code: ONEDAYMD
Here are the top 10 ETF picks for August 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. Current market conditions and upcoming events like the U.S. Federal Reserve’s September meeting make August a timely opportunity to reallocate or accumulate: 1. SPDR S&P 500 ETF Trust (SPY) or Vanguard S&P 500 ETF (VOO) Broad U.S. equity exposure; strong performers with SPY up 8.9% YTD and focused on the AI rally and potential post-rate-cut growth ( 1 , 2 ). Would buy: Yes, for long-term core holding and growth. 2. iShares Core S&P 500 ETF (IVV) Similar to SPY/VOO, highly liquid, low expense ratio. Would buy: Yes, for passive U.S. equity exposure ( 2 ). 3. Mirae Asset Defence Tech ETF or MarketVector Global Defense Industry ETF Defense sector ETFs are up 45%...
Gold and silver ETFs are outperforming the S&P 500 index. But do these precious metals deserve a place in your investment portfolio? We provide a list of the best precious metals ETFs by 2025 performance, as well as the benefits and risks that investors need to know before buying these funds. The best gold and silver ETFs of 2025 stand out due to exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Here are the top options across global and key regional markets as of July 2025: Best Gold ETFs of 2025 SPDR Gold MiniShares Trust (GLDM) 1-Year Return: 43.90% Expense Ratio: 0.10% Notes: Best performing gold ETF, tracks physical gold, high liquidity, and cost-effective for retail investors ( 1 , 2 ). iShares Gold Trust Micro (IAUM) 1-Year Return: 43.86% Expense Ratio: 0.09% Notes: Nearly matches GLDM in returns, with the lowest expense ratio among major gold ETFs ( 1 ). abrdn Physical Gold Shares ETF (S...
Top gold ETFs to watch in 2025 span U.S., Indian, Europe and Chinese markets, offering both physical gold exposure and mining stock leverage. Based on the latest performance, expense ratios, and trends, key ETFs include: SPDR Gold MiniShares Trust (GLDM) : The best-performing gold ETF by one-year return in 2025, up around 44%, with a very low expense ratio (0.10%). It tracks physical gold closely and is highly liquid, making it a top choice for cost-conscious investors seeking strong recent gains ( 2 , 1 ). iShares Gold Trust Micro (IAUM) : Nearly matching GLDM’s performance with a 43.86% one-year gain and an even lower expense ratio (0.09%), this is an excellent low-cost option for gold exposure ( 2 ). abrdn Physical Gold Shares ETF (SGOL) : With about a 43.8% one-year return and expense ratio around 0.17%, this fund holds physical gold bullion and appeals to investors seeking stable, direct gold exposure ( 2 , 1 ). GraniteShares Gold Trust (BAR) : Tracks physica...
Here are the top 10 pharmaceutical companies by market cap as of July 2025. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This mid-2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com ...
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). While earnings and revenue reports are considered lagging indicator...
Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boas...
If you are looking for the best credit cards for hospital bills in Singapore , you've come to the right place. Whether you're dealing with big doctors' bills right now or regularly spend on your health, you may be interested in a credit card that offers rewards for medical spend. Most credit cards actively exclude hospital spend from earning rewards. So, to make things easier, the experts from Value Champion have scoured the terms & conditions of 100+ cards in Singapore to find which actually do provide cash rebates or miles. Earning Rewards on Hospital Bills & Why We Selected these Cards Medical bills, whether for a doctor or a hospital visit, can be quite expensive and are sometimes difficult to pay off all at once. Facing such a large bill can certainly be daunting, but doing so also presents the opportunity to earn significant cashback or miles (the greater the spend, the greater the return). Additionally, some credit cards offer 0% interest instalment plans wh...
As August 2025 unfolds, investors are eagerly seeking opportunities to capitalize on the market’s strongest performers. Driven by rapid advancements in artificial intelligence, the accelerating global energy transition, and robust demand for technology infrastructure, certain companies stand out as frontrunners poised for substantial growth. This article highlights the top 10 stocks expected to outperform in August 2025, providing insights into their recent momentum, sector leadership, and the key trends fueling their rise. Whether you’re looking to boost your portfolio with cutting-edge innovators or aiming for steady gains through resilient industries, these companies represent some of the most compelling investment prospects in the current market landscape. Based on recent trends and analyst forecasts for August 2025, the following companies are expected to outperform: 1. Nvidia (NVDA) NVIDIA (NVDA) is rated a "Strong Buy" by a consensus of analysts, with 44–64 analysts (d...
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Comments